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I. Introduction 
Insulin and aldosterone have long teen recognized to 
play important roles in potassium homeostasis. Both have 
been shown to participate in feed-back control circuits 
whereby rises in the plasma potassium concentration stim¬ 
ulates the release of each hormone (1,33). Increased 
levels of plasma aldosterone, in turn, stimulates both 
the renal excretion (33-36) and the extrarenal cellular 
uptake (34,38) of potassium. The primary influence of 
insulin on potassium balance is to augment extrarenal 
uptake of potassium, predominantly by liver and skeletal 
muscle (4-,6-11). Recent studies have suggested that epi¬ 
nephrine and other sympathomimetic substances may also play 
an important role in maintaining potassium homeostasis (2, 
51). More specifically, beta-adrenergic agonist agents have 
been shown to ameliorate the rise in serum potassium concen¬ 
tration following the administration of potassium chloride in 
cats (2,49). However, "whether such a protective effect 
exists in man and the mechanisms underlying this effect have 
not been completely studied. It is the purpose of the pres¬ 
ent thesis to examine whether catecholamines exert a protec¬ 
tive effect against hyperkalemia in man and to define the 
mechanism or mechanisms by which such an effect might occur. 
Attention will also be given to the possible interrelation- 

ships between the protective effect of catecholamines on 
potassium tolerance and the previously described insulin 
and aldosterone feed-back systems. 

II. Overview 
3 
A. Insulin and Potassium 
Insulin infusion has long been known to lower the 
serum potassium concentration (3). This effect is thought 
to he mediated by promoting the transfer of extracellular 
potassium into ceils, particularly liver and skeletal muscle 
(4,6-11). Andres and coworkers (10) employing the forearm 
perfusion technique in human subjects were among the first to 
demonstrate that insulin stimulated skeletal muscle uptake of 
potassium. Furthermore, the insulin mediated stimulation of 
potassium uptake occurred at levels of insulin that had no 
effect on muscle uptake of glucose. Glucose uptake, however, 
did move to enhance potassium uptake. In addition, Zierler 
(6-8) and others (9) have found that incubation of muscle tis¬ 
sue in vitro with insulin causes intercellular accumulation 
of potassium and hyperpolarization of the cell membranes even 
In the absence of glucose in the incubation medium. The mole¬ 
cular mechanism of this action of insulin has not been com¬ 
pletely elucidated but it has been postulated that this effect 
of insulin on potassium is part of the chain of events which 
results in cellular uptake of glucose (6,8). Insulin-mediated 
uptake by liver cells has been less well defined. Early 
studies by Penn et al. (3) suggested that the liver disposed 
of potassium following insulin administration. More recently, 

4 
DeFronzo and coworkers, employing hepatic venous catheteri¬ 
zation in combination with the insulin clamp technique, have 
shown that over half of the potassium disappearing from the 
extracellular space following insulin administration can be 
accounted for by hepatic uptake (12). An effect of insulin 
on potassium uptake by the brain has also been demonstrated 
(13) but this is small compared to the muscle and liver 
uptake. 
The clinical importance of insulin in maintaining 
potassium homeostasis is particularly evident in diabetic 
subjects. When these patients are given an exogenous glu¬ 
cose infusion creating a state of hyperglycemia, no change 
or a slight rise in serum potassium occurs (ll). This is 
in contrast to normal subjects in whom hyperglycemia leads 
to a decline in serum potassium concentration through elicit¬ 
ing secretion of insulin (ll). It has been postulated that 
hyperglycemia causes the osmotic extraction of fluid and 
electrolytes (predominantly potassium) from the intercellular 
environment (13)- Glucose induced insulin release is respons¬ 
ible for the transport of potassium back into cells. In dia¬ 
betics who lack both insulin and the second important potas¬ 
sium regulatory hormone aldosterone, hyperglycemia may thus 
result in lethal hyperkalemia (11,14,15). 
While changes in the circulating insulin levels may 
effect serum potassium concentrations, it has also been dis¬ 
covered that basal insulin levels play a role in potassium 
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homeostasis. DeRronzo and coworkers (15,16) have shown that 
in normal subjects and maturity-onset diabetics who retain 
the ability to secrete insulin, the inhibition of basal 
insulin secretion with somatostatin results in a significant 
rise in serum potassium concentration of 0.5 to 0.6 mEq/1 
without a change in urinary potassium excretion. In contrast, 
a similar administration of somatostatin to Juvenile-onset 
diabetics who lack endogenous insulin release has no effect 
on serum potassium concentration. Replacement of basal 
insulin levels by continuous insulin infusion in the control 
group reversed the somatostatin induced rise in serum potas¬ 
sium. Somatostatin has also been shown to markedly impair 
the ability of dogs to dispose of an acutely administered 
potassium load (16). Again, replacement of basal insulin 
levels restored potassium tolerance to normal. Thus, main¬ 
tenance of basal insulin levels plays an important role in 
the defense against hyperkalemia. 
In order to complete the circuit of a proposed insulin- 
potassium feedback loop, it is necessary to show that potas¬ 
sium is capable of stimulating the release of insulin. Such 
an effect has been demonstrated in the isolated, perfused 
rat (17) and dog (18) pancreas, and following potassium infu¬ 
sion in the dog (19) and in man (20). However, in most of 
these studies, the increment in plasma potassium concentration 
necessary to stimulate insulin release was in excess of 1.5 to 
2.0 mEq/1. In studies where the plasma potassium concentration 
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was raised by less than 1.5 to 2.0 mEq/1, it has been dif¬ 
ficult to demonstrate an increase in circulating insulin 
levels. Thus, Sterns et al. (21) found no change in plasma 
insulin levels during a potassium infusion which raised the 
plasma potassium concentration by a mean of 1.15 mEq/1, and 
Dluhy and coworkers (20) likewise failed to observe a rise in 
plasma insulin concentrations in response to an infusion of 
potassium which raised the serum potassium concentration by 
1.5 to 2.0 mEq/1. Complicating the interpretation of these 
data is the fact that the portal vein insulin concentration 
may be four to five times the measured peripheral insulin 
concentration (22). It is thus possible that even small 
increments in plasma potassium concentration may result in 
significant insulin secretion which, because of the large 
extraction of insulin by the liver would not be reflected in 
the periphery. Such unmeasured insulin could still be active 
in effecting potassium metabolism in the liver. Support for 
this thesis comes from the work of Bleckard et al. who found 
a significant rise in the portal vein insulin concentration 
following potassium chloride administration without a change 
in peripheral insulin levels (22). Since recent studies by 
DeFronzo and coworkers (12) have shown the liver to be an 
important site of insulin mediated potassium uptake, local 
increases in portal vein insulin concentrations may play an 
important role in potassium homeostasis. However, even in the 
absence of a rise in plasma insulin concentration levels, the 

maintenance of basal insulin levels has been shown to play 
an important role in potassium homeostasis. 
Insulin has also been related to potassium excretion 
in studies by DePronzo et al. (23) who showed that physio¬ 
logic hyperinsulinemia is associated with a decline in the 
rate of urinary potassium excretion. However, this seemed 
to be secondary to a fall in plasma, and thus filtered, 
potassium concentration. A direct effect of insulin of 
renal tubular handling of potassium was not demonstrable in 
studies with dogs. 
B. Aldosterone and Potassium 
Aldosterone is an adrenal steroid hormone which medi¬ 
ates the exchange of sodium and potassium in the distal renal 
tubule. Though many factors influence aldosterone secretion, 
potassium is known to be a potent aldosterone secretagogue. 
Potassium has been found by McCaa et al. (24) to be a more 
potent aldosterone secretagogue than angiotensin II in dogs 
chronically administered either potassium or angiotensin II. 
This stimulatory effect has also been shown in isolated rat 
and human (25) adrenal cortical cells incubated in vitro 
with potassium, in isolated adrenal glands perfused with 
potassium and in intact dogs (24,26,27), and in man (28) per¬ 
fused with potassium. Bluhy and coworkers have demonstrated 
the release of aldosterone in man without an increment in 
serum potassium during potassium infusion (28). This effect 
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■was observed in nephrectomized and hypophysectomized animals 
thereby eliminating renin and ACTH as primary stimuli to 
aldosterone secretion. Infusion of potassium into adrenal 
arteries resulted in aldosterone release without a rise in 
peripheral potassium concentration indicating again that 
potassium is a direct aldosterone secretogogue. In the oppo¬ 
site direction, infusion of glucose or insulin which lowers 
the serum potassium concentration by as little as 0.3 mEq/1 
has been shown to decrease aldosterone levels by fifty per 
cent (28). These data indicate that physiologic decreases 
as well as increases in potassium concentration are important 
regulators of aldosterone secretion. These effects of potas¬ 
sium have been shown to be independent of dietary sodium 
intake and to occur in anephric patients (l). 
In addition to its effect on aldosterone release, potas¬ 
sium has also been shown to exert a stimulatory effect on 
aldosterone synthesis. Potassium increases the activity of 
the 18-hydroxylase enzyme which catalyzes the penultimate 
step in aldosterone synthesis (29). This effect has been 
demonstrated in cultured zona glomerulosa adrenal cells (29). 
In human subjects, with the terminal part of the aldosterone 
synthesis pathway isolated with metyrapone (30), a requirement 
for potassium has been found with the initial step in aldos¬ 
terone synthesis as well. This confirms earlier work by 
Kaplan et al. (31). 
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More recently, Catt (32) lias shown that potassium 
also plays a permissive role for other aldosterone secre- 
tagogues. Using isolated zona glomerulosa cells he demon¬ 
strated that a decrease in the incubation potassium concen¬ 
tration markedly inhibits the activity of angiotensin and 
ACTH to stimulate aldosterone release. 
The importance of aldosterone in maintaining normal 
potassium homeostasis has been recognized for years. Aldos¬ 
terone deficiency is known to result in hyperkalemia (33) 
while aldosterone excess is associated with hypokalemia (3^)« 
In contrast to insulin, which exerts its major effect on 
extrarenal potassium handling, aldosterone acts primarily by 
augmenting renal potassium excretion (35?36). Thus, in ani¬ 
mals the ability of the distal nephron to excrete potassium is 
markedly impaired, and acute and chronic potassium tolerance 
is diminished, in the absence of aldosterone. 
Some evidence does exist, however, that aldosterone 
may play a small role in extrarenal potassium homeostasis as 
well. Alexander and Levinsky (37) found that nephrectomized 
rams on a high potassium diet had a better potassium toler¬ 
ance following an acute potassium load than those kept on a 
normal potassium diet. Their results indicate that an extra¬ 
renal effect of aldosterone on potassium handling exists that 
is dependent on a state of chronic hyperaldosteronism second¬ 
ary to a high potassium diet. A possible cellular mechanism 
for this effect comes from the work of Adler (38) who found 
that aldosterone enhances potassium uptake by skeletal muscle 

cells in vitro, and that this enhancement is greater at 
elevated concentrations of potassium (7-5 mEq/l) in the 
incubation medium. 
In summary, elevation of the serum potassium concen¬ 
tration results in increased synthesis and release of 
aldosterone which in turn enhances both renal and extra 
renal potassium disposal. 
C. Epinephrine and Potassium 
D'Silva was the first to suggest that epinephrine 
might play a role in potassium homeostasis (39)- He found 
that an intravenous infusion of epinephrine into anesthetized 
cats resulted in a triphasic response in the plasma potassium 
concentration. Within the first two minutes following epi¬ 
nephrine administration, there was a small rise in the plasma 
potassium concentration. This was followed by a decrease in 
the concentration to levels 1 mEq/l below the baseline value 
by ten minutes following epinephrine administration. Subse¬ 
quently, the plasma potassium concentration slowly returned 
to baseline over the nexh thirty minutes. This effect of 
epinephrine was mimicked by the sympathomimetic agent ephe- 
drine and abolished by ergotamine, a sympatholytic agent. 
The triphasic response of plasma potassium concentration to 
epinephrine infusion has been observed many times since this 
first report (40). 
Employing hepatic catheterization in cats, D'Silva 
further found that the liver was the sire of the potassium 
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release responsible for the initial rise in the potassium 
concentration following epinephrine administration (41). 
Eepatectomy abolished the early hyperkalemic effect of epi¬ 
nephrine completely. D*Silva, and subsequently Brewer (42), 
have shown by the same technique that the second phase 
decline in plasma potassium concentration following epineph¬ 
rine infusion is largely the result of hepatic sequestration 
of potassium (4,43,44). 
An extrahepatic effect of epinephrine on potassium 
homeostasis has been suggested in the work of several inves¬ 
tigators showing an effect of epinephrine on skeletal muscle 
potassium uptake (44,45). Epinephrine infusion into the 
femoral artery of dogs enhances the arterial-venous plasma 
potassium concentration difference indicating that peripheral 
uptake of potassium has occurred. That this increased uptake 
is probably accounted for by muscle tissue is suggested by 
studies in cats (2) and frogs (45) demonstrating increased 
potassium content of skeletal muscle following epinephrine 
induced hypokalemia. 
The mechanism of the initial hyperkalemic effect of 
epinephrine has been shown by Vick and coworkers (46,47) to 
be mediated by alpha adrenergic receptors. The subsequent: 
hypokalemia, conversely, is shown to be due to beta-adrenergic 
receptor stimulation. Pre-treatment with the specific alpha 
agonist phenoxybenzamine inhibited the initial rise and aug¬ 
mented the subsequent fall in plasma potassium concentration 
following epinephrine administration indicating that the 
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alpha agonistic effects of epinephrine are predominantly 
hyperkalemic. When phenoxybenzamine -was administered alone, 
a decline in the potassium concentration ensued indicating a 
role for basal alpha sympathetic activity in potassium homeo¬ 
stasis (47). Infusion of the specific a3.pha agonist phen¬ 
ylephrine caused a rise in the plasma potassium concentration 
supporting these results. Pretreatment with the specific beta 
sympathetic agonist propranolol prevented the secondary fall 
in the potassium level following epinephrine administration, 
indicating that beta receptor stimulation is responsible for 
the hypokalemic phase of the epinephrine response. This find¬ 
ing is supported by the observation that isoproterenol, a pure 
beta stimulant, causes a fall in the plasma potassium concen¬ 
tration to a greater extent than with epinephrine. Interest¬ 
ingly, changes in the potassium concentration following the 
infusion of isoproterenol and phenylephrine followed closely 
those with epinephrine administration, confirming its mixed 
alpha and beta activity (48). finally, in limited studies in 
man, propranolol was found to block the hypokalemic effect of 
a 10 ug/min epinephrine infusion (48). 
In summary, the effect of epinephrine on potassium 
metabolism results from combined alpha and beta adrenergic 
stimulation with the alpha effect predominating initially 
and the beta effect later. The initial hyperkalemic effect 
is mediated via hepatic potassium release while both skeletal 
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muscle and liver uptake of potassium play a role in the sub¬ 
sequent hypokalemic effect. 
The protective effect of beta stimulation on potassium 
tolerance has been further studied by Lum and Lockwood (2, 
4-9). In cats infused with potassium to the point of fatal 
cardiac toxicity, epinephrine was found to ameliorate the 
rise in plasma potassium concentration and increase survival. 
The specific beta-2 agonists soterenol and salbutamol mimicked 
this protective effect but the specific beta-1 stimulant 
l-isopropyl-2-(2-thiazoxy)-2 propanol did not. Similarly, 
the specific beta-2 antagonist butoxamine abolished the pro¬ 
tective effect of epinephrine while the specific beta-1 
antagonist practolol did not. Thus, the beta-2 adrenergic 
receptor appears to be the mediator of the hypokalemic effects 
of epinephrine. Interestingly, in Lum and Lockwood's work, 
the protective effect of epinephrine in acutely induced hyper¬ 
kalemia persisted in pancreatectomized animals, excluding any 
role for insulin. 
finally, there is evidence that epinephrine infusion 
causes changes in renal potassium metabolism. In contrast 
to its effect on the systemic circulation, epinephrine causes 
an increase in renal vascular resistance and a concomitant 
reduction in renal blood flow (50). Renin secretion is also 
enhanced by epinephrine and would be expecred to increase 
potassium excretion by the kidney. The changes in renal hemo¬ 
dynamics have been shown by Smythe et al. (51) to be associated 
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with a marked decrease in potassium excretion without any 
change in glomerular filtration rate by an as yet unclear 
mechanism. 
D. Epinephrine and Insulin 
Epinephrine has been shown to inhibit insulin secre¬ 
tion in a variety of experimental systems: isolated perfused 
pancreas (52) and in intact man and animals (53-55)• Porteet 
al. (54,55) showed that infusion of epinephrine into human 
subjects resulted in hyperglycemia (ISO mg/dl) yet no increase 
in serum immunoreactive insulin (IPE) occurred. A similar 
degree of hyperglycemia following glucose infusion without 
epinephrine resulted in an immediate and significant increase 
in serum insulin levels. When the epinephrine infusion was 
stopped in the former study, an abrupt increase in the insulin 
level to three-fold above basal ensued. Porte also showed 
that epinephrine inhibited the rise in serum insulin concen¬ 
tration following glucose, glucagon and tolbutamide adminis¬ 
tration. Infusion of phentolamine, an alpha adrenergic block¬ 
ing agent, reversed the inhibitory effect of epinephrine and 
the insulin concentration role (56). In contrast, isopro¬ 
terenol, a beta adrenergic agonist, was found to stimulate 
insulin release. These observations indicate that the effect 
of alpha adrenergic stimulation is to inhibit insulin release 
while beta adrenergic stimulation results in insulin secre¬ 
tion. 
■ 
The effect of epinephrine on insulin secretion has been 
further defined with more frequent sampling and prolongation 
of epinephrine infusion in human subjects (56,57)- An initial 
fall in serum insulin levels occurred during the first fif¬ 
teen minutes of epinephrine infusion and this was followed 
by a gradual rise to baseline by sixty minutes, and to levels 
two-fold above basal at one hundred and twenty minutes. The 
initial decline was reversed by phentclamine, and the subse¬ 
quent recovery, by propranolol. A similar effect has been 
reported in the isolated perfused dog pancreas (52). 
Finally, the effect of endogenous sympathetic activity 
on basal insulin secretion has been investigated by the infu¬ 
sion of phentolamine or propranolol alone. Phentolamine led 
to an increase in the serum insulin levels whereas propranolol 
resulted in a fall (58). Neither infusion had an effect on 
the serum glucose concentration. 
Thus, as with epinephrine and potassium, the relation¬ 
ship between epinephrine and insulin seems to be dependent on 
a balance between alpha and beta adrenergic mechanisms. The 
predominant effect of epinephrine at the rate of infusion 
used in most studies (6jig/min) is an inhibition of insulin 
release which is mediated through alpha adrenergic receptors; 
an increase in insulin secretion is observed following beta 
adrenergic stimulation. A similar effect of epinephrine has 
also been documented with more physiologic doses of epineph¬ 
rine (20-60jig/min) in human subjects (58). 
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E. Epinephrine and Aldosterone 
Sympathetic stimulation is one of the recognized fac¬ 
tors which stimulates renin secretion from the kidney and 
thus, indirectly, aldosterone release from the adrenal cor¬ 
tex (59). A direct effect of epinephrine on aldosterone 
synthesis or release has not been described. 
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III. Purpose 
The present study seeks to define the role of epineph¬ 
rine in potassium homeostasis in human teings. Previous 
studies have largely dealt with epinephrine induced changes 
in plasma potassium concentration in anesthetized laboratory 
animals and have employed pharmacological doses of epineph¬ 
rine, resulting in serum epinephrine levels even above those 
found in conditions of stress. In studies involving potas¬ 
sium infusion in conjunction with epinephrine infusion to 
test epinephrine's effect on potassium tolerance, the dose 
of potassium chloride employed was also pharmacologic with 
resulting plasma potassium concentrations in the 8 to 10 
mEq/1 range, and cardiac toxicity and death employed as the 
endpoint. Whether epinephrine plays a protective role in 
ameliorating rises in plasma potassium concentration within 
the physiologic range has not been examined. In addition, 
no studies have been performed in which changes in renal 
handling of potassium were measured and correlated with 
changes in plasma potassium concentration during epinephrine 
or epinephrine and potassium chloride infusion. Similarly, 
the influence of epinephrine on insulin and aldosterone, 
hormones known to effect potassium homeostasis, was never 
evaluated in these previous studies. Finally, the effect 
of changes in plasma potassium concentration on catecholamine 
secretion has not previously teen defined. It is to these 
questions that the present study is addressed. 
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IV. Methods 
A„ Subjects 
Six healthy volunteers were obtained ranging in age 
from 18 to 22 years (mean 19-5 - 0.7 yr). 
(Table I). There were 5 males and 1 female, ho sub¬ 
ject had any significant past medical illness, none was 
taking any medications, and all were consuming a diet con¬ 
taining at least 200 grams of carbohydrate per day for three 
days prior to study. One patient had a family history of 
diabetes mellitus. Informed, written consent was obtained 
from each subject prior to their participation in the study. 
B. Experimental Protocol 
All studies were performed in the postabsorptive state 
at 8 a.m. following a 12 hour overnight fast. All subjects 
remained recumbent during the study except to void. Prior 
to study, polyethylene catheters were inserted under local 
xylocaine anesthesia into an antecubital vein for blood samp¬ 
ling and into a femoral vein for the infusion of all test 
substances. All subjects were given a distilled water load 
(15 ml/kg) followed by enough distilled water orally to 
ensure voiding every 30 minutes. Following the collection 
of two to three baseline urine samples, the infusion of test 
substances was begun. Each subject participated in three 
sequential studies and thereby served as his own control. 
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In the first study (Figure l), potassium chloride 
(Potassium Chloride Injection, IVNEX Pharmaceuticals, 
Chagrin Falls, Ohio) was infused via a constant infusion 
pump (Model 979 Compact Infusion Pump, Harvard Apparatus, 
Millis, Mass.) at a rate of 0.75 mEq/kg over two hours. The 
potassium chloride was dissolved in half-normal saline solu¬ 
tion and infused at the rate of 0.74 ml/min. The study was 
continued for an additional two hours after stopping the 
potassium infusion. In the second study, subjects received 
the same potassium chloride infusion as in the first study. 
In addition, a constant infusion of epinephrine chloride 
(Adrenalin Chloride Solution 1:1000, Parke-Davis and Co., 
Detroit, Mich.) at the rate of 0.05 pig/kg/min was started 
30 minutes prior to beginning the potassium infusion and was 
continued throughout the four hour study period. The epi¬ 
nephrine was dissolved in half-normal saline and was admin¬ 
istered at the rate of 0.27 ml/min. In the third study, potas¬ 
sium chloride and epinephrine were administered as above. In 
addition, a constant infusion of propranolol hydrochloride 
(Inderal, Ayerst Laboratories, Inc., New York. N.Y.) given 
at the rate of 1.43 pig/kg/min was begun concomitantly with 
the epinephrine. The propranolol was dissolved in half- 
ncrmal saline and infused at the rate of 0.27 ml/min. 
Blood pressure, heart rate and electrocardiogram were 
monitored at 15-30 minute intervals throughout each study. 
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Following at least two baseline samples, blood samples 
were drawn at 15-30 minute intervals throughout the study and 
analyzed for potassium, sodium, glucose, insulin, aldosterone, 
creatinine, epinephrine and norepinephrine. A total of 400 
ml of blood was drawn per study. The sum of infused solutions 
including normal saline to flush the blood drawing catheter 
was also approximately 400 ml. 
Urine samples were collected at 30 minute intervals 
during the study and were analyzed for potassium, sodium and 
creatinine. 
C. Analytical Determinations 
Potassium and sodium concentrations in plasma and urine 
were determined by flame spectrophotometry (Flame Photometer 
Model 143, Instrumentation Laboratory, Lexington, Mass.) 
using lithium as the internal standard. Plasma and urine 
creatinine concentrations were determined by the method of 
Jaffe adapted to the Auto Analyzer (60). Methods for the 
determination of plasma insulin (61) and plasma aldosterine 
(62) have been previously published. Plasma epinephrine and 
norepinephrine concentrations were determined by radioenzym- 
atic assay (63) in the laboratory of Dr. Robert Sherwin. 
Plasma glucose concentration was determined by the glucose 
oxidase method (Glucose Analyzer, Beckman Instrument, 
Fullerton, C.A.). 

D. Calculations 
2 
Creatinine clearance was calculated by the formula: 
cGr = UV/P 
where U is the urinary creatinine concentration, V is the 
urine volume and P is the plasma creatinine concentration. 
Urinary potassium excretion rate was calculated by 
the formula: 
K 
exc 
where Ug is the urinary potassium concentration, V is the 
urine volume and t is the time of urine collection in min¬ 
utes. K is expressed as >iEq/min. 
The net amount of potassium excreted for any given 
time period was calculated as the difference between the 
mean rate of potassium excretion during the time period and 
the mean baseline potassium excretion rate, times the time. 
The net sodium excretion was calculated in a similar 
manner to that for net potassium excretion. 
The amount of potassium that was translocated into 
cells during any given time period was calculated from the 
difference between the expected rise in plasma potassium 
concentration and the actual rise in the plasma potassium 
ccncentratio2i muitipled by the extracellular fluid volume 
as follows: 
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cellular uptake 
of potassium = (expected rise in Pv - 
(mEq) K 
actual rise in P^.) x ECV 
= K • n, — K inf_exc 
ECV 
AP- K obs x ECV 
where is the total amount of potassium infused (mEq), 
K is the net amount of potassium excretion (mEq), APf/ , 
is the net observed rise in plasma potassium concentration 
(mEq/l) over the two hour potassium infusion and the subse¬ 
quent two hour measurement period, and ECV is the extracel¬ 
lular fluid volume calculated as 15% of body weight (liters) 
The incremental area under the plasma potassium concen 
tration-time curves was calculated using the trapezoidal rul 
approximation and was carried out by the subroutine QA01AS 
of the Harwell Subroutine Library of the Yale University I Eli 
570/158 computer. It is expressed as mEq/l x min. 
E. Statistical Analysis 
Values are expressed as the mean i SEW. Comparison 
of groups was performed with the paired t-test (64). Linear 
regression was used for curve fitting. 

V. Results 
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A. Vital Signs 
During the potassium chloride infusion alone, no 
change in heart rate or blood pressure was observed. When 
epinephrine was infused with potassium chloride, a variable 
increase in heart rate (15-20 beats per min) and a widening 
of pulse pressure (10-20 mm Hg) occurred. Subjectively, 
most subjects reported feelings of tremulousness and a 
pounding heart beat which was most marked at the beginning 
of the epinephrine infusion and subsided after the first 
sixty minutes. When propranolol was added to the potassium 
chloride and epinephrine infusion, no change in heart rate 
or pulse pressure was observed and no subjective sensations 
were reported by any volunteer. 
B. Potassium 
During the potassium chloride infusion alone baseline 
plasma potassium concentration (3*77 - 0.11 mEq/l) rose by 
a maximum of 0.83 - 0.09 mEq/l (p <0.001) (Figure 2). This 
maximum rise occurred at two hours into the study when the 
potassium chloride infusion was stopped. Thereafter, the 
plasma potassium concentration progressively declined and 
was 0.38 - 0.14 mEq/l above basal values at the end of the 
study. Urinary potassium excretion increased significantly 
from a mean baseline rate of 37 - 12 pEq/min to a mean maxi- 
imum rate of 184 ± 15 uEa/min (p < 0.001) (Figure 3) without a 

change in creatinine clearance (Figure 4). 47 1 4% of the 
infused potassium -was excreted during the four hour study 
period (Figure 5)« Of the infused potassium that was 
retained within the body at the end of the four hour study 
period, 24.8 1 1.17 mEq was translocated into cells (Figure 
6). This represented 82 1 5% of the retained potassium 
(Figure 7) and 43 ± 3% of the total amount of potassium admin¬ 
istered (Figure 8). The incremental area in plasma potassium 
during the 0-120 and 0-240 minute time periods was 65-3 - 5-8 
and 126.5 - 16.2 mEq/1 x min respectively (Figure 9). The 
incremental area in plasma potassium expressed per amount of 
potassium retained during the same time periods was 1.5 - 0.2 
and 4.2 1 0.5 min./l (Figure 10). 
When epinephrine was infused alone for 30 minutes pre¬ 
ceding potassium chloride infusion, the plasma potassium con¬ 
centration fell from a baseline value of 3*66 i 0.10 mEq/1, 
which was similar to that in the first study, to 0.61 ± 0.06 
mEq/1 below baseline 30 minutes after beginning the epineph¬ 
rine infusion (p<0.00l) (Figure ll). When potassium chlor¬ 
ide infusion was added to the epinephrine infusion, the rise 
in plasma potassium concentration was significantly less than 
with potassium chloride infusion alone during the first 120 
minutes (p< 0.001) (Figure 2). During the last two hours fol¬ 
lowing potassium chloride administration, the elevation of 
the plasma potassium concentration above baseline was not 
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statistically significantly different from that observed 
with potassium chloride infusion alone. Easeline urinary 
excretion rate for potassium (U^V) was 37 - 7 jiEq/min and 
was similar to that with potassium infusion alone (Figure 3)» 
Following epinephrine infusion, however, U^V actually fell to 
a mean value, 21 1 3 ^iFq/min, which was significantly below 
the basal excretion rate (p<0.00l) and was markedly less 
than the maximal excretion rate in the study with potassium 
chloride infusion alone (p<O.QOl). Creatinine clearance 
did not change during this study. The total potassium 
excreted over the four hour study period fell below that 
expected to result from continued basal rates of potassium 
excretion (p<0.00i) (Figure 5)« Despite the marked decline 
in Ugh/" the plasma potassium concentration actually rose less 
in this study because the amount of potassium translocated 
into cells increased by over 100% in comparison to the 
amount translocated with potassium chloride infusion alone 
(p<0.00l) (Figures 6 and 7)- The incremental area in plasma 
potassium was significantly less than with potassium chloride 
infusion alone for all time periods (p^ 0.005) (Figure 10). 
When propranolol was infused with epinephrine for 30 
minutes preceding potassium chloride infusion, the plasma 
potassium concentration did not change significantly from 
the baseline value of 3-69 - 0.11 mEq/1, which itself was 
similar to the baseline plasma potassium concentrations in 
the two previous studies. When potassium chloride infusion 

was added to the epinephrine and propranolol infusions, 
the rise in plasma potassium concentration above baseline 
was significantly greater than with potassium chloride 
infusion alone during the first 120 minutes (p <0.01) 
(Figure 2) and tended to remain high for the duration of 
the study. Ug-V (Figure 3) was significantly less during 
the first 120 minutes of the study than in the study with 
potassium infusion alone (p< 0.01) but was not different 
during the remainder of the study. Creatinine clearance 
(Figure 4) was unaffected by the addition of propranolol. 
The percentage of the potassium chloride dose excreted 
(Figure 5) was 9 ± 2% at 120 minutes and 31 - 6% at 240 
minutes with epinephrine and propranolol infusion and was 
significantly less than with potassium infusion alone 
(p<0.001 and p<0.02). The absolute amount as well as the 
percentage of the dose of potassium that was translocated 
into cells tended to be increased with propranolol (Figures 
6 and S) but did not reach statistical significance. The 
incremental area in plasma potassium (Figures 9 and 10) also 
tended to be greater with the addition of propranolol to the 
infusate. 
During the potassium chloride infusion alone the 
increase in the urinary potassium excretion rate correlated 
linearly with the increase in plasma potassium concentration 
over the time of the collection of each urine sample (Figure 
12) (r = 0.81, p <0.001). Following the addition of 
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epinephrine or epinephrine and propranolol to the infusate 
no correlation between the change in PE and the change in 
U-^V could be demonstrated. 
C. Sodium 
Baseline plasma sodium concentration was similar in 
all three studies and was unaffected by potassium chloride, 
epinephrine or propranolol infusion. The baseline urinary 
sodium excretion rate was also similar in all three studies 
and rose following potassium chloride infusion (Figure 13)• 
The rise with epinephrine and potassium chloride infusion, 
however, was significantly less (p<0.02) than with potas¬ 
sium chloride infusion alone or with the addition of pro¬ 
pranolol to epinephrine and potassium. 
D. Glucose 
Basting plasma glucose concentration was similar in the 
potassium chloride (85-2 1 1.8 mg/dl), the potassium and 
epinephrine (83-7 - 2.8 mg/dl), and the potassium, epineph¬ 
rine and propranolol (79-8 ± 2.8) studies. Plasma glucose 
concentration remained unchanged during the potassium chlor¬ 
ide infusion. When epinephrine was added to the infusate, 
an immediate and significant rise in the plasma glucose con¬ 
centration occurred and the glucose concentration remained 
elevated throughout the duration of the study (Pigure 14). 
The plasma glucose concentration when propranolol was infused 
with potassium chloride and epinephrine also rose significantly 
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above the baseline value but remained significantly less 
than the level in the potassium chloride and epinephrine 
study (p< 0.001). 
E. Insulin 
Baseline plasma insulin concentration was similar in 
all three studies (Figure 15)• No change in the insulin 
concentration occurred following potassium chloride infusion 
alone. Epinephrine infusion resulted in a 15 to 20 ^lU/ml 
increase in the plasma insulin concentration which correlated 
temporally with the rise in plasma glucose concentration. 
This rise in the insulin level persisted throughout the four 
hour study period. When propranolol was administered along 
with epinephrine, an initial small decline in the plasma 
insulin concentration was observed (Figure 15) but there¬ 
after the plasma insulin values were not significantly dif¬ 
ferent from those in the potassium chloride infusion alone. 
F. Epinephrine and Norepinephrine 
Baseline plasma epinephrine and norepinephrine concen¬ 
trations during the potassium chloride infusion study alone 
were 16.2 ± 8.0 pg/ml and 420.1 1 107.2 pg/ml respectively 
(Figurne 16). Following infusion of potassium chloride, no 
significant change in either catecholamine was observed. 
G. Aldosterone 
Results pending. 
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VI. Discussion 
The homeostatic mechanisms which control the net bal¬ 
ance and cellular distribution of potassium in living sys¬ 
tems are complex and interrelated. This is necessary 
because potassium plays a vital role in the function of all 
cells, particularly in nerve and muscle tissue where elec¬ 
trical activity relies on the balance of intra- and extra¬ 
cellular potassium concentration. The contributions of 
insulin and aldosterone to internal and external potassium 
balance have been elucidated in some detail and the impor¬ 
tance of each of these hormones in normal as well as abnor¬ 
mal states in controlling potassium homeostasis has been 
recognized. The present study indicates that epinephrine 
and probably other sympathomimetic agents also play an 
important role in both renal and extra-renal potassium 
metabolism. 
Previous studies in animals, employing the infusion 
of pharmacological doses of epinephrine and potassium have 
demonstrated that epinephrine ameliorates the rise in plasma 
potassium concentration and decreases the incidence of fatal 
cardiac arrythmia (2,49). The present study extends these 
earlier observations to man and documents that more physio¬ 
logic elevations in plasma epinephrine levels, similar to 
those observed in stress (65), are capable of blunting the 
rise in plasma potassium concentration following the infusion 
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of small amounts of potassium. In the present study, each 
subject received an infusion of epinephrine at the rate of 
0.05 ;ag/kg/min for 30 minutes prior to the administration 
of potassium. During this period, the plasma potassium 
concentration declined by 0.42 ± 0.05 mEq/1 during the first 
15 minutes and by 0.61 1 0.06 mEq/1 by 30 minutes. This 
decline could not be accounted for by an increase in plasma 
insulin concentration; insulin remained unchanged at 15 
minutes and was only slightly elevated at 30 minutes. Three 
of six subjects showed no rise in plasma insulin concentra¬ 
tion during the first 30 minutes post epinephrine infusion 
yet demonstrated a significant decline in plasma potassium 
concentration. When potassium was administered following 
pretreatment with epinephrine, the rise in plasma potassium 
concentration during the first two hours was significantly 
attenuated. This blunted rise in plasma potassium concen¬ 
tration is even more striking when changes in urinary potas¬ 
sium excretion are taken into account. Eollowing potassium 
chloride infusion alone, 47% of the infused potassium was 
excreted. This value agrees well with those previously 
reported under similar experimental conditions (66). When 
epinephrine was infused along with potassium chloride urin¬ 
ary potassium excretion was markedly inhibited and actually 
fell below baseline values (p< 0.001). When the rise in 
plasma potassium concentration is viewed in the context of 
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the amount of infused potassium which is retained within 
the body, a greater than 100% increase in the amount of 
potassium translocated into cells was observed (Figures 6 
and 10). The importance of this protective effect of epi¬ 
nephrine on potassium tolerance would assume particular sig¬ 
nificance during conditions of stress. Under such circum¬ 
stances, protein breakdown is accelerated and a state of 
net catabolism exists. This would be expected to result in 
a net efflux of potassium from the intracellular to the 
extracellular compartment at a time when both insulin secre¬ 
tion (56,67) and insulin action (68) are significantly 
impaired. Since stress is known to stimulate epinephrine 
release, the increased circulating levels of this hormone 
could exert a protective effect against the development of 
hyperkalemia. 
The sites of the stimulatory effect of epinephrine on 
cellular uptake of potassium are not discernible in the pres¬ 
ent study. Previous work, however, suggests that both the 
liver and skeletal muscle are quantitatively the most impor¬ 
tant tissues that participate in epinephrine-mediated potas¬ 
sium disposal. The mechanism by which epinephrine augments 
cellular uptake of potassium is most likely related to stim¬ 
ulation of beta adrenergic receptors since the augmentation 
can be blocked by propranolol. Recent studies have demon¬ 
strated the presence of beta receptors on both liver and 
skeletal muscle cells (69,70). In spite of this, an indirect 

effect of epinephrine, mediated via stimulation of insulin 
or aldosterone secretion cannot he excluded by the present 
study. The latter would seem unlikely, however, since the 
effect of epinephrine on potassium is immediate while the 
increase in plasma aldosterone does not occur until 30 to 
60 minutes (71) following epinephrine administration, and 
the onset of action of aldosterone in stimulating potassium 
transport in the kidney is delayed by an additional 60 to 
120 minutes (72). That part of the effect of epinephrine on 
enhancing potassium uptake is mediated via insulin cannot be 
excluded. Although the initial decline in plasma potassium 
concentration during the first 30 minutes of epinephrine 
infusion prior to potassium infusion cannot be explained by 
stimulation of insulin secretion, the blunted rise in plasma 
potassium concentration during potassium chloride infusion 
could be explained in part by release of insulin secondary 
to the epinephrine-induced hyperglycemia. Previous studies, 
employing much higher doses of epinephrine have demonstrated 
a complete inhibition of insulin secretion despite the pres¬ 
ence of hyperglycemia (53-56). In the present study, employ¬ 
ing much lower doses of epinephrine, it is likely that the 
beta adrenergic inhibitory effect of epinephrine on insulin 
secretion was insufficient to completely block the effect of 
hyperkalemia on the pancreatic beta cell, and the alpha 
adrenergic stimulatory effect of epinephrine on insulin 
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secretion predominated. In any event, it is clear that in 
terms of potassium metabolism, an intermediary role for 
insulin cannot be ruled out in this study. Infusion of 
insulin to levels similar to those observed in response to 
epinephrine infusion in the present study have been shown 
to result in increased cellular uptake of potassium and a 
fall in plasma potassium concentration (12). However, the 
magnitude of this fall was significantly less than that 
observed in the present study with epinephrine infusion 
leaving open the possibility of a direct role for epineph¬ 
rine in ameliorating the rise in plasma potassium following 
potassium infusion. Studies are presently in progress to 
evaluate what role, if any, insulin plays in the epinephrine- 
mediated hypokalemic effect. In these studies, somatostatin 
is infused to inhibit insulin secretion and basal insulin 
levels are replaced with an exogenous infusion of insulin. 
The same infusion of potassium chloride and epinephrine will 
then be administered while plasma insulin levels are main¬ 
tained at basal. Any observed hypokalemic effect would then 
be attributable to epinephrine alone. 
The effect of epinephrine on potassium tolerance can¬ 
not be explained by enhanced renal excretion of potassium 
since this excretion is decreased markedly following epi¬ 
nephrine infusion. This anti-kaluretic effect cannot be 
explained by a fall in the peritubular capillary potassium 
concentration perfusing the distal nephron or by a fall in 
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the filtered load of potassium since the plasma potassium 
concentration increased following potassium chloride infu¬ 
sion and the glomerular filtration rate was unchanged. Epi¬ 
nephrine is known to decrease renal plasma flow (30,51)* 
however, and it is possible that the total amount of potas¬ 
sium presented to the distal potassium secretory sites 
actually diminished, leading to a decrease in the potassium 
excretion rate, even though the plasma potassium concentra¬ 
tion rose. Alternatively, a direct inhibitory effect of epi¬ 
nephrine on peritubular potassium uptake is possible. This 
seems unlikely, though, since one would have to postulate 
that the renal tubular cell is different from other cells 
where epinephrine stimulates potassium uptake (7-10). 
Following epinephrine infusion, the rise in urinary 
sodium excretion was not as great as with potassium infu¬ 
sion alone (Figure 13)• Although this relative decrease 
(compared with potassium chloride alone) in sodium excre¬ 
tion could explain a blunted rise in renal potassium excre¬ 
tion, it cannot explain the absolute decrease in potassium 
excretion that was actually observed. 
Since epinephrine is known to increase aldosterone 
secretion (57) (results from present study pending) over a 
prolonged time course and insulin has no known effect on 
renal potassium handling (23), it is unlikely that changes 
in the circulating levels of these hormones would effect 
renal potassium excretion in the present study. 
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The infusion of propranolol in conjunction with epi¬ 
nephrine and potassium chloride reverse almost completely 
the renal and extra-rena1-effects of epinephrine indicating 
that the effect of epinephrine on potassium metabolism is 
mediated by stimulation of beta adrenergic receptors. The 
addition of propranolol effectively blocked the inital fall 
in plasma potassium concentration observed with epinephrine 
infusion alone, and prevented the protective effect of epi¬ 
nephrine on potassium tolerance. In fact, the rise in plasma 
potassium concentration when propranolol was infused with 
epinephrine and potassium chloride was actually greater than 
with potassium chloride alone. Renal excretion was returned 
/ 
almost to normal by propranolol but the rate was still less 
than with potassium infusion alone indicating that the pro¬ 
pranolol was not completely blocking the effects of epineph¬ 
rine on potassium excretion at the doses of the two drugs 
used. Propranolol also markedly decreaseed cellular uptake 
of potassium that would have proceeded under the influence 
of epinephrine alone (figures 6 and 7)» 
The deleterious effects of propranolol on potassium 
tolerance could be explained in several ways, first, it is 
possible that during the potassium chloride infusion alone 
the rise in plasma potassium concentration stimulates epi¬ 
nephrine release from the adrenal medulla or leads to local 
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release of epinephrine at sympathetic nerve terminals iner- 
vating liver and skeletal muscle cells (73)» Propranolol, 
hy blocking this stimulatory effect of' potassium, could have 
a detrimental effect on potassium tolerance. Preliminary 
measurements of circulating catecholamines during the potas¬ 
sium chloride infusion, however, fail to demonstrate a con¬ 
sistent increase in circulating plasma epinephrine levels 
(Figure 16). However, this could not exclude the possibility 
that a rising plasma potassium concentration could activate 
sympathetic nerve fibers innervating muscle and liver cells 
with local uptake and degradation of epinephrine. Such local 
epinephrine metabolism has been shown to occur by Axelrod 
(75)• It is also possible that basal levels of epinephrine 
or sympathetic nervous activity are necessary to dispose of 
an exogenous potassium load normally and that propranolol, 
by inhibiting basal epinephrine release or sympathetic ner¬ 
vous system activity, leads to impaired potassium tolerance. 
This would be similar to the situation with insulin where 
inhibition of basal insulin secretion by as little as 50% 
results in a marked impairment in potassium tolerance. Fur¬ 
ther studies are now in progress with potassium chloride and 
propranolol infusion alone to investigate this question. 
The results in the present study also exclude a direct 
effect of propranolol mediated by mechanisms other than 
inhibition of beta adrenergic receptors stimulation. When 
propranolol was infused with epinephrine, insulin levels 
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fell slightly (2 to 5 jiU/ml). This decrease was not signifi¬ 
cantly different from control after the first 15 minutes of 
potassium chloride infusion and in 3 of 6 subjects no decrease 
at all in plasma insulin concentration was observed. These 
results make it unlikely that the decrement in potassium 
tolerance can be explained by inhibition of insulin release. 
Likewise, the time course of the inhibitory effect of pro¬ 
pranolol on aldosterone secretion would be too long to explain 
the present results. Measurement of plasma aldosterone con¬ 
centrations are pending and will directly answer this ques¬ 
tion. If it indeed becomes clear that basal sympathetic 
activity is important in potassium tolerance and homeostasis 
in general it would raise the question of whether potassium 
tolerance is compromised in states of functional sympathect¬ 
omy such as diabetic neuropathy or propranolol use for ische¬ 
mic heart disease. 
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VII. Summary 
In summary, the present study documents that physio¬ 
logic elevations of circulating plasma epinephrine concen¬ 
trations ameliorate the rise in plasma potassium concentra¬ 
tion following a potassium chloride infusion. This effect 
is the result of enhanced cellular uptake of potassium and 
can he completely reversed hy propranolol, indicating that 
epinephrine's protective effect on potassium tolerance is 
mediated via stimulation of "beta adrenergic receptors. 
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Subject 
1 
2 
3 
4 
5 
Table I. Subject Profile 
Age 
(yrs.) Sex 
Height 
(cm) 
Weight 
(kg) 
22 M 188 76 
21 M 186 82 
IS M 192 96 
20 1 160 65 
18 M 172 71 
18 M 186 76 6 
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